SelectQuote backs BrainCheck
BrainCheck, the cognitive healthcare platform for physicians, announced $10 million in Series B funding. The round is led by Next Coast Ventures and S3 Ventures, with additional investors including Nueterra Capital, Tensility Ventures, and True Wealth Ventures. In addition, UPMC Enterprises and SelectQuote Insurance Services have joined as strategic investors. The round takes the total capital raised by BrainCheck to date to $20 million.
BrainCheck’s technology acts as a bridge between patients and neurologists, replacing pencil-and-paper tests to measure brain health. Through 10-15-minute tests, performed in-person or remote (via a smartphone, tablet or computer), cognitive function can be detected early and more accurately. Based on the test, patients are assigned a Cognitive Quotient score, which is then used to produce a personalized cognitive care plan. Over 400 neurology, primary care and geriatrics practices use the technology currently, including Mount Sinai clinicians.
SelectQuote is joining as a strategic investor following the launch of Population Health, its new healthcare services company that helps Medicare-eligible individuals access the benefits they’re entitled to. When cognitive concerns are identified in SelectQuote’s standard Health Risk Assessment, a Population Health associate will help the individual access and complete a BrainCheck test and guide them either to their primary care physician or a provider in the Population Health network for further assessment and diagnosis as needed.
“We are at the forefront of improving access to cognitive assessment and care. With early diagnosis comes treatment and intervention. These funds will allow us to accelerate the adoption of our platform and work with clinicians to help more patients live better and safer lives, decrease caregiver frustration, and save health systems trillions of dollars. I believe that BrainCheck can help cognitive care evolve the way cancer care has since the 1970s, when chemotherapy was one-size-fits-all.” – Yael Katz, PhD, co-founder and CEO of BrainCheck.
“BrainCheck shows promise as a cognitive assessment tool that would allow patients to independently complete the test while allowing physicians to spend more time reviewing the results and planning care with patients.” – Dr. Adele Towers, director of risk adjustment at UPMC Enterprises and a geriatric medicine specialist at UPMC.
“BrainCheck is a breakthrough platform that has the potential to transform how we diagnose and treat cognitive impairment. The combination of technical sophistication and ease of use makes BrainCheck a perfect tool for doctors and health systems everywhere. I’m so impressed by what Dr. Katz and her team have achieved to date and am excited to support the team as they continue to innovate and scale.” – Michael Smerklo, co-founder and managing director of Next Coast Ventures.
